SPYGLASS PHARMA INC (SGP) Stock Price & Overview
NASDAQ:SGP • US85220G1094
Current stock price
The current stock price of SGP is 22.34 USD. Today SGP is down by -0.53%. In the past month the price decreased by -14.99%.
SGP Key Statistics
- Market Cap
- 712.869M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
SGP Stock Performance
SGP Stock Chart
SGP Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SGP.
SGP Earnings
SGP Forecast & Estimates
9 analysts have analysed SGP and the average price target is 46.67 USD. This implies a price increase of 108.89% is expected in the next year compared to the current price of 22.34.
SGP Groups
Sector & Classification
SGP Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SGP Ownership
SGP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.72 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.88 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.44 | 298.838B | ||
| PFE | PFIZER INC | 9.42 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.4 | 121.374B | ||
| ZTS | ZOETIS INC | 16.65 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.31 | 28.018B | ||
| VTRS | VIATRIS INC | 5.32 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.6 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.39 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SGP
Company Profile
SpyGlass Pharma Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Aliso Viejo, California and currently employs 65 full-time employees. The company went IPO on 2026-02-06. SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused in the development of the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The firm develops a non-bioerodible drug delivery technology, designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye. Its lead product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System) is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma or ocular hypertension.
Company Info
IPO: 2026-02-06
SPYGLASS PHARMA INC
27081 Aliso Creek Road, Suite 125
Aliso Viejo CALIFORNIA US
Employees: 65
Phone: 13026587581
SPYGLASS PHARMA INC / SGP FAQ
What does SGP do?
SpyGlass Pharma Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Aliso Viejo, California and currently employs 65 full-time employees. The company went IPO on 2026-02-06. SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused in the development of the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The firm develops a non-bioerodible drug delivery technology, designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye. Its lead product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System) is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma or ocular hypertension.
Can you provide the latest stock price for SPYGLASS PHARMA INC?
The current stock price of SGP is 22.34 USD. The price decreased by -0.53% in the last trading session.
What is the dividend status of SPYGLASS PHARMA INC?
SGP does not pay a dividend.
What is the ChartMill technical and fundamental rating of SGP stock?
SGP has a ChartMill Technical rating of 2 out of 10.You can find more details on the Technical Analysis and Fundamental Analysis tabs.
On which exchange is SGP stock listed?
SGP stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of SGP stock?
SPYGLASS PHARMA INC (SGP) operates in the Health Care sector and the Pharmaceuticals industry.
What is the outstanding short interest for SPYGLASS PHARMA INC?
The outstanding short interest for SPYGLASS PHARMA INC (SGP) is 1.85% of its float.